Effect of early administration of sacubitril/valsartan in ST-elevation myocardial infarction patients undergoing PCI: Impact on infarct size and ventricular remodeling

Background: Adverse left ventricular remodeling remains a major determinant of heart failure and mortality in patients with ST-elevation myocardial infarction (STEMI) despite successful primary percutaneous coronary intervention (PCI). Sacubitril/valsartan has shown beneficial effects on ventricular remodeling in heart failure populations; however, evidence regarding its early initiation following STEMI remains limited. Objectives: To evaluate the association of early sacubitril/valsartan initiation with infarct-size markers and ventricular remodeling outcomes in STEMI patients undergoing primary PCI. Methods: This retrospective observational cohort study included 150 consecutive STEMI patients treated with primary PCI at Tianjin Hospital, China, between January 2020 and December 2024. Patients were categorized into an angiotensin receptor–neprilysin inhibitor (ARNI) group receiving sacubitril/valsartan within 7 days of STEMI or a control group receiving standard ACEI/ARB therapy. Ventricular remodeling was assessed using serial echocardiographic measurements including left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). Clinical outcomes were evaluated with a minimum follow-up of 6 months. Results: Baseline demographic and procedural characteristics were comparable between groups. Patients receiving early sacubitril/valsartan demonstrated lower peak cardiac biomarker levels and greater improvement in follow-up LVEF compared with the control group. Adverse ventricular remodeling occurred less frequently in the ARNI group. Heart failure–related hospitalizations were lower among patients receiving sacubitril/valsartan, whereas all-cause mortality and adverse event rates were comparable between groups. Multivariable analysis demonstrated that early sacubitril/valsartan initiation was associated with favorable ventricular remodeling. Conclusion: Early sacubitril/valsartan initiation after STEMI treated with primary PCI was associated with improved ventricular remodeling and better recovery of left ventricular systolic function in this retrospective cohort. These findings should be considered hypothesis-generating and require confirmation in larger prospective randomized studies.

Authors

Institutions

Publication Details

Journal
Pakistan Journal of Pharmaceutical Sciences
Published
2026-11-18
DOI
https://doi.org/10.36721/pjps/2026.40.16612.1
Primary Topic
Acute Myocardial Infarction Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect of early administration of sacubitril/valsartan in ST-elevation myocardial infarction patients undergoing PCI: Impact on infarct size and ventricular remodeling

Lei Sun
1 links
Pakistan Journal of Pharmaceutical Sciences
Acute Myocardial Infarction Research
article

Effect of early administration of sacubitril/valsartan in ST-elevation myocardial infarction patients undergoing PCI: Impact on infarct size and ventricular remodeling

Lei Sun
article en

Abstract

Background: Adverse left ventricular remodeling remains a major determinant of heart failure and mortality in patients with ST-elevation myocardial infarction (STEMI) despite successful primary percutaneous coronary intervention (PCI). Sacubitril/valsartan has shown beneficial effects on ventricular remodeling in heart failure populations; however, evidence regarding its early initiation following STEMI remains limited. Objectives: To evaluate the association of early sacubitril/valsartan initiation with infarct-size markers and ventricular remodeling outcomes in STEMI patients undergoing primary PCI. Methods: This retrospective observational cohort study included 150 consecutive STEMI patients treated with primary PCI at Tianjin Hospital, China, between January 2020 and December 2024. Patients were categorized into an angiotensin receptor–neprilysin inhibitor (ARNI) group receiving sacubitril/valsartan within 7 days of STEMI or a control group receiving standard ACEI/ARB therapy. Ventricular remodeling was assessed using serial echocardiographic measurements including left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV). Clinical outcomes were evaluated with a minimum follow-up of 6 months. Results: Baseline demographic and procedural characteristics were comparable between groups. Patients receiving early sacubitril/valsartan demonstrated lower peak cardiac biomarker levels and greater improvement in follow-up LVEF compared with the control group. Adverse ventricular remodeling occurred less frequently in the ARNI group. Heart failure–related hospitalizations were lower among patients receiving sacubitril/valsartan, whereas all-cause mortality and adverse event rates were comparable between groups. Multivariable analysis demonstrated that early sacubitril/valsartan initiation was associated with favorable ventricular remodeling. Conclusion: Early sacubitril/valsartan initiation after STEMI treated with primary PCI was associated with improved ventricular remodeling and better recovery of left ventricular systolic function in this retrospective cohort. These findings should be considered hypothesis-generating and require confirmation in larger prospective randomized studies.

Pakistan Journal of Pharmaceutical Sciences
Tianjin Hospital (CN)
Good health and well-being
Acute Myocardial Infarction Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon